DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Rilotumumab is an investigational drug.
There have been 11 clinical trials for Rilotumumab. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2012.
The most common disease conditions in clinical trials are Stomach Neoplasms, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and Southwest Oncology Group.
There are thirteen US patents protecting this investigational drug and two hundred and thirty international patents.
Recent Clinical Trials for Rilotumumab
|A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer||Amgen||Phase 3|
|Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer||National Cancer Institute (NCI)||Phase 2/Phase 3|
|Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer||Southwest Oncology Group||Phase 2/Phase 3|
Top disease conditions for Rilotumumab
Top clinical trial sponsors for Rilotumumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Rilotumumab||Start Trial||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||Start Trial|
|Rilotumumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Rilotumumab||Start Trial||Cancer treatment with c-met antagonists and correlation of the latter with HGF expression||Genentech, Inc. (South San Francisco, CA)||Start Trial|
|Rilotumumab||Start Trial||Method for predicting efficacy of c-Met inhibitor||SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)||Start Trial|
|Rilotumumab||Start Trial||Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF||SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)||Start Trial|
|Rilotumumab||Start Trial||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Rilotumumab||European Patent Office||2954056||2033-02-08||Start Trial|
|Rilotumumab||Hong Kong||1218930||2033-02-08||Start Trial|
|Rilotumumab||World Intellectual Property Organization (WIPO)||2014124326||2033-02-08||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|